Seres Therapeutics
MCRB
76 hedge funds and large institutions have $820M invested in Seres Therapeutics in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
177% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 13
10% more funds holding
Funds holding: 69 → 76 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less capital invested
Capital invested by funds: $1.03B → $820M (-$208M)
39% less call options, than puts
Call options by funds: $931K | Put options by funds: $1.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.96M |
| 3 |
BM
Bridger Management
New York
|
+$8.61M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$8.07M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$3.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.33M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.91M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$507K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$282K |
| 5 |
OPPM
Opus Point Partners Management
New York
|
-$227K |
MCRB Hedge Fund Activity: Q1 2016 in Review
76 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2016, worth a combined $820M — down 20% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MCRB positions and 4 closed out — a net gain of 9 holders — while 36 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $10.5M. The largest seller was Millennium Management, cutting an estimated $4.33M.
- 76 institutional investors held Seres Therapeutics (MCRB) as of Q1 2016, up from 69 in Q4 2015.
- Funds reported $820M of Seres Therapeutics stock for Q1 2016, down 20% quarter-over-quarter.
- 13 funds opened new Seres Therapeutics positions in Q1 2016 and 4 closed out, a net change of +9 holders.
- The largest Seres Therapeutics buyer in Q1 2016 was Vanguard Group, an estimated $10.5M added.
- The largest Seres Therapeutics seller in Q1 2016 was Millennium Management, an estimated $4.33M sold.
Based on aggregated 13F filings for Q1 2016.